EMERYVILLE, Calif., Nov. 01, 2016 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will present at the Stifel 2016 Healthcare Conference in New York on Tuesday, November 15th 2016 at 9:30 a.m. Eastern Time.
The presentation will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events.cfm and available for approximately two weeks.
About Adamas Pharmaceuticals, Inc.
Adamas is a pharmaceutical company that is developing new medicines to improve the daily lives of those affected by chronic neurologic disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and epilepsy. Adamas has pioneered a platform based on an understanding of time-dependent biologic effects of disease activity and drug response to potentially achieve symptomatic relief without additional tolerability issues. We have developed a portfolio of Chrono-Synchronous Therapies (CSTs) to address chronic neurologic disorders. In addition to ADS-5102, we are investigating ADS-4101 for the improved control of epileptic seizures. Additionally through our license agreement with Forest Laboratories Holding Ltd. (a wholly owned subsidiary of Allergan plc), we are eligible to receive royalties on sales of NAMENDA XR® and NAMZARIC® beginning in June of 2018 and May of 2020, respectively. For more information, please visit www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are registered trademarks of Merz Pharma GmbH & Co. KGaA.
Contact: Martin Forrest VP Corporate Communications and Investor Relations 510-450-3528


Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Instagram Outage Disrupts Thousands of U.S. Users
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Washington Post Publisher Will Lewis Steps Down After Layoffs 



